Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial Academic Article Article uri icon


MeSH Major

  • Antigens, Neoplasm
  • Gene Expression Regulation, Developmental
  • Membrane Proteins
  • Neoplasm Proteins
  • Placenta
  • Trophoblasts


  • Despite the results of the in vitro studies, a Phase II trial failed to demonstrate significant antitumor activity for suramin in patients with cisplatin-refractory germ cell tumors. Although the dosing of suramin by the nomogram was not associated with neurotoxicity, the time needed to achieve therapeutic levels was lengthy, and the levels, once achieved, were of short duration. Thus, an alternative means of administration, i.e., by intermittent bolus administration, is being investigated in trials for patients with prostatic carcinoma. The lack of definitive efficacy for suramin in this trial has led the authors to consider other agents in Phase II trials for cisplatin-refractory germ cell tumor.

publication date

  • January 1993



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1002/1097-0142(19931201)72:11<3313::AID-CNCR2820721129>3.0.CO;2-C

PubMed ID

  • 8242558

Additional Document Info

start page

  • 3313

end page

  • 7


  • 72


  • 11